scholarly article | Q13442814 |
P50 | author | Thomas E. Starzl | Q1248240 |
Ron Shapiro | Q59747328 | ||
John Julian Fung | Q61476062 | ||
Ngoc J Thai | Q61826131 | ||
Amit Basu | Q96123399 | ||
Henkie P Tan | Q114340592 | ||
Amadeo Marcos | Q115134365 | ||
P2093 | author name string | Akhtar Khan | |
Deanna Blisard | |||
Kusum Tom | |||
P2860 | cites work | History of clinical transplantation | Q24596303 |
Acquired immunologic tolerance: with particular reference to transplantation | Q33567138 | ||
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation | Q34201121 | ||
Antigen localization and migration in immunity and tolerance | Q34239865 | ||
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath | Q34304820 | ||
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus | Q34359751 | ||
Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy | Q34561556 | ||
Transplantation tolerance from a historical perspective | Q34572212 | ||
The impact of Campath 1H induction in adult liver allotransplantation | Q38514430 | ||
Tolerogenic immunosuppression for organ transplantation | Q41116219 | ||
Pancreatic transplantation at the University of Pittsburgh | Q41785260 | ||
Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation | Q44419266 | ||
Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. | Q44461489 | ||
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). | Q44514934 | ||
Campath-1H in renal transplantation: The University of Wisconsin experience. | Q45092670 | ||
Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation | Q46478191 | ||
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. | Q46485560 | ||
A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring | Q46670432 | ||
Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results | Q46702767 | ||
Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression | Q46816120 | ||
Intestinal transplantation for short bowel syndrome and gastrointestinal failure: current consensus, rewarding outcomes, and practical guidelines. | Q53257876 | ||
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients | Q61651688 | ||
Specificity of monoclonal antibody Campath-1 | Q70213447 | ||
Tolerance for organ recipients: a clash of paradigms | Q79145851 | ||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pancreas | Q9618 |
P304 | page(s) | 1621-1624 | |
P577 | publication date | 2006-12-01 | |
P1433 | published in | Transplantation | Q15730500 |
P1476 | title | Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes | |
P478 | volume | 82 |
Q42943652 | Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin |
Q39991648 | Alemtuzumab: key for minimization of maintenance immunosuppression in reconstructive transplantation? |
Q37425990 | Immunosuppression and rejection in human hand transplantation |
Q38162892 | Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective |
Q37738864 | Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date |
Q40956691 | Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression |
Q38558078 | Opportunistic infections complicating solid organ transplantation with alemtuzumab induction |
Q83893794 | Pancreas transplantation |
Q34699278 | Pancreas transplantation: The Wake Forest experience in the new millennium |
Q35128345 | Pancreas transplantation: lessons learned from a decade of experience at Wake Forest Baptist Medical Center |
Q35963432 | Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation |
Q46340832 | The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation |
Search more.